Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

Launched by BEIJING ANLONG BIOPHARMACEUTICAL CO., LTD. · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the long-term safety and effectiveness of a treatment called AL-001, which is given as an injection in the eye, specifically targeting a condition known as wet age-related macular degeneration (wAMD). This trial is looking for patients who have already participated in a previous study where they received a single dose of AL-001. The goal is to see how well the treatment works over a longer period and to monitor any side effects that might occur.

To be eligible for this study, participants must have previously received the AL-001 injection and need to agree to take part by signing a consent form. There are no specific exclusions, meaning most people who meet the inclusion criteria can join. If you participate, you can expect to attend scheduled visits to monitor your health and the treatment's effects. This study is currently recruiting participants of all genders and ages 18 and older who are interested in helping researchers learn more about this treatment for wAMD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
• • The subject or their legal representative agrees to participate in this study and signs a written ICF.
• • The subjects are willing and able to follow planned visits and procedures.
• Exclusion Criteria:
• • None